Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06478121

Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE)

Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE) — Recruiting • Cardiology / Cardiovascular • NCT06478121.

📅 25 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06478121
Sponsor
University of Exeter
Start
2025-11-11
ClinicaliQ Trial Snapshot
  • Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE) — Recruiting • Cardiology / Cardiovascular • NCT06478121.
  • This observational 'recruit by genotype' study aims to provide insights into the cellular and molecular pathways underlying beta cell disorders and their physiological consequences. Eligible individuals are those with and without a pathogenic genetic variant, acting as case and control, respectively. Using….
  • Sponsor: University of Exeter.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This observational 'recruit by genotype' study aims to provide insights into the cellular and molecular pathways underlying beta cell disorders and their physiological consequences. Eligible individuals are those with and without a pathogenic genetic variant, acting as case and control, respectively. Using a "recruit by genotype" approach, the researchers will perform detailed and specific analysis according to the individual's genetic variant. The study's main aims are to : 1) identify and describe biomarkers and cellular features in blood samples that occur because of the rare causal genetic variant; 2) study…

Eligibility Snapshot
  • * Mental capacity to give informed consent * Of any sex, ethnicity, location. * Group 1: Cases will have a genetic variant(s) resulting in a beta cell disorder. * Group 2: Controls will not have a genetic variant(s) resulting in a beta cell disorder and will be matched to a Case for sex, age (+/- 15%) and BMI (+/- 3 kg/m2).

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
Heart Failure: Diagnosis and Management (NICE NG106)
Cardiology / Cardiovascular · 27 Mar 2026
Use NT-BNP or BNP testing in primary care to rule out heart failure; refer urgently to secondary care if elevated with compatible…
View guideline →
Guideline
Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Cardiology / Cardiovascular · 25 Mar 2026
Percutaneous insertion of catheter-based left ventricular microaxial flow pumps may be considered for patients with acute cardiogenic shock refractory to medical therapy…
View guideline →
Clinical Brief
Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation
Cardiology / Cardiovascular · MHRA · 24 Oct 2024
A safety review has been conducted by the MHRA following a Yellow Card report concerning a patient who was taking bromocriptine. The…
View brief →
Clinical Brief
The struggle to get hold of medication in England is set to get worse
Cardiology / Cardiovascular · BBC Health · 01 May 2026
Drug supply shortages are affecting multiple therapeutic areas – patients with cardiovascular disease, stroke prevention, ophthalmology, and psychiatric conditions are currently experiencing…
View brief →